Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for type 2 diabetes
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 2 diabetes or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on type 2 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Effect of Ramadan fasting on glycaemic parameters & body mass index in type II diabetic patients: A meta-analysis. There has been an ongoing debate about the impact of Ramadan fasting (RF) on the health of these individuals who fast during Ramadan. The aim of this meta-analysis was to evaluate the relationship between RF and glycaemic parameters in type2diabetes mellitus (T2DM) patients.Search terms were decided and databases such as MEDLINE EBSCO, Google Scholar and EMBASE were searched
Cardiovascular Risk and Safety Evaluation of a Dual Peroxisome Proliferator-Activated Receptor-Alpha/Gamma Agonist, Aleglitazar, in Patients With Type2Diabetes: A Meta-analysis. This study evaluates the cardiovascular risk and safety of a dual peroxisome proliferator-activated receptor alpha and gamma (PPARα&γ), aleglitazar, for the management of type2diabetes mellitus. Studies were identified after a literature search in electronic databases and included in the meta-analysis according
Effects of Dipeptidyl Peptidase-4 Inhibitors on Renal Outcomes in Patients with Type2Diabetes: A Systematic Review and Meta-Analysis. To investigate the effects of dipeptidyl peptidase-4 (DPP-4) inhibitors on renal outcomes in patients with type2 diabetes.MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials were searched to identify randomized controlled trials (RCTs) of DPP-4 inhibitors from inception to September 2017. We selected eligible RCTs comparing DPP-4 inhibitors
Effect of Supervised Exercise Program on Individuals in Peripheral Arterial Disease with Type2Diabetes Mellitus - A Systematic Review. Type2Diabetes Mellitus (T2DM) is usually accompanied by various micro and macro vascular complications. Peripheral Arterial Disease (PAD) is one of the major complications of diabetes which is accountable for morbidity and mortality throughout the world. The first line of treatment in these individuals is life style modification and exercise
Impact of interventions to reduce overnutrition on healthcare costs related to obesity and type2diabetes: a systematic review. In recent decades, obesity and type2diabetes mellitus (T2DM) have both become global epidemics associated with substantial healthcare needs and costs.The aim of this review was to critically assess nutritional interventions for their impact on healthcare costs to community-dwelling individuals regarding T2DM or obesity or both, specifically using CHEERS
The effect of Ramadan fasting on cardiovascular events and risk factors in patients with type2diabetes: A systematic review. Ramadan is the fasting month in Islam. Muslims around the world observe Ramadan every year, including people with diabetes. Data on the association of fasting in people with diabetes are sparse. The purpose of this study is to assess the association of fasting on cardiovascular risk factors and events in people with diabetes. A comprehensive search was conducted (...) in the following database: Embase, Medline, Cochrane library and CINAHL. The following key terms were used: Ramadan, Ramazan, Ramadhan, Muslim, Islam and fasting. Studies were eligible if they included people with Type2diabetes who fasted during Ramadan and reporting results on cardiovascular risk factors or events. Overall 22 studies met inclusion criteria for the review; five studies reported cardiovascular outcomes and 17 reported changes in risk factors. There is insufficient evidence to link Ramadan
Systematic review of salutogenic-oriented lifestyle randomised controlled trials for adults with type2diabetes mellitus. Describe the characteristics (development, intensity, deliverers, setting, strategies) and assess the effect of salutogenic-oriented lifestyle interventions on physical and psychosocial health outcomes in adults with type2diabetes mellitus (T2DM).PubMed, Scopus and PsycINFO were systematically searched for randomised controlled trials (RCTs) published up to August 2019
Prediction models for development of retinopathy in people with type2diabetes: systematic review and external validation in a Dutch primary care setting. The aims of this study were to identify all published prognostic models predicting retinopathy risk applicable to people with type2diabetes, to assess their quality and accuracy, and to validate their predictive accuracy in a head-to-head comparison using an independent type2diabetes cohort.A systematic search was performed in PubMed (...) and Embase in December 2019. Studies that met the following criteria were included: (1) the model was applicable in type2diabetes; (2) the outcome was retinopathy; and (3) follow-up was more than 1 year. Screening, data extraction (using the checklist for critical appraisal and data extraction for systemic reviews of prediction modelling studies [CHARMS]) and risk of bias assessment (by prediction model risk of bias assessment tool [PROBAST]) were performed independently by two reviewers. Selected
[Meta-analysis of effect of Jinqi Jiangtang Tablets on treating insulin resistance in type2diabetes]. To systematically assess the efficacy and safety of Jinqi Jiangtang Tablets for patients with insulin resistance in type2diabetes, literatures were retrieved in 7 databases: PubMed, EMbase, Cochrane Library, Chinese National Knowledge Infrastructure(CNKI), WanFang database, Chinese BioMedical Database(CBM), VIP Chinese Science and Technique Journals Database, from the date of its inception (...) Tablets showed a significant decrease in 2 h BG combined with Western medicine compared with Western medicine alone(WMD=-1.46, 95%CI[-1.71,-1.21], P<0.000 01). Jinqi Jiangtang Tablets combined with Western medicine showed a significant decrease in HbA1 c(WMD=-0.75, 95%CI[-0.97,-0.53], P<0.000 01), FINS(WMD=-0.65, 95%CI[-0.80,-0.50], P<0.000 01), 2 h INS(SMD=-1.67, 95%CI[-2.26,-1.09], P<0.000 01) and HOMA-IR(WMD=-1.22, 95%CI[-1.67,-0.76], P<0.000 01). Jinqi Jiangtang Tablets combined
Dose-response associations between serum creatinine and type2diabetes mellitus risk: A Chinese cohort study and meta-analysis of cohort studies. This study aims to investigate the association between serum creatinine and risk of type2diabetes mellitus (T2DM) based on a cohort analysis and meta-analysis of cohort studies.We enrolled 41 439 participants aged ≥18 years without T2DM at baseline, who had ≥2 health examinations based on an ongoing prospective cohort in Beijing. Cox proportional (...) (Pnonlinearity = .082) and an increased risk of T2DM with each 0.1-mg/dL decrease in serum creatinine (RR = 1.07; 95% CI 1.04, 1.09).The cohort study and meta-analysis provide further evidence supporting the negative association between serum creatinine and T2DM risk in a linear dose-response pattern.Low serum creatinine level was associated with increased risk of type2diabetes mellitus (T2DM) among people who were overweight and obese. A linear association was found between serum creatinine and T2DM risk
Cardiovascular Outcomes With the Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type2Diabetes and Chronic Kidney Disease: An Updated Meta-Analysis of Randomized Controlled Trials. Diabetes mellitus (DM) and chronic kidney disease (CKD) significantly increase the risk of cardiovascular morbidity and mortality. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are a new class of hypoglycemic agents that have shown significant promise in the reduction of cardiovascular events (...) . Current guideline recommendations do not support the use of these agents in patients with CKD stage 3 or higher. We performed a comprehensive meta-analysis to evaluate their cardiovascular effects in patients with type2DM and CKD stage 3 or higher. A comprehensive search was performed in PubMed, Cochrane central, and Embase. Software R was utilized to perform a meta-analysis via the generic inverse variance method. Additionally, we conducted a network meta-analysis to compare the relative efficacy
Prevention of Type2Diabetes by Lifestyle Changes: A Systematic Review and Meta-Analysis. Prevention of type2diabetes (T2D) is a great challenge worldwide. The aim of this evidence synthesis was to summarize the available evidence in order to update the European Association for the Study of Diabetes (EASD) clinical practice guidelines for nutrition therapy. We conducted a systematic review and, where appropriate, meta-analyses of randomized controlled trials (RCTs) carried out in people (...) seven RCTs (N = 4090) fulfilled the eligibility criteria and were included in the meta-analysis. The diagnosis of incident diabetes was based on an oral glucose tolerance test (OGTT). The overall risk reduction of T2D by the lifestyle interventions was 0.53 (95% CI 0.41; 0.67). Most of the trials aimed to reduce weight, increase physical activity, and apply a diet relatively low in saturated fat and high in fiber. The PREDIMED trial that did not meet eligibility criteria for inclusion in the meta
Insulin pumps for people with Type 1 Diabetes 1 Driving better decision-making in healthcare Continuous subcutaneous insulin infusion therapy for treating type 1 diabetes Technology Guidance from the MOH Medical Technology Advisory Committee Published on 23 March 2020 Guidance recommendations The Ministry of Health Medical Technology Advisory Committee has recommended: ? Continuous subcutaneous insulin infusion therapy (CSII) and its consumables as a treatment option for adults and children (...) with type 1 diabetes mellitus: o who use multiple daily injections of insulin (MDI) to achieve target HbA1c but result in the person experiencing disabling hypoglycaemia, where disabling hypoglycaemia is defined as the repeated and unpredictable occurrence of hypoglycaemia that results in persistent anxiety about recurrence and is associated with a significant adverse effect on quality of life (QoL); or o who have unacceptably high HbA1c (i.e. at 8.5% or above) on MDI despite a high level of care, where
Insulin glargine/lixisenatide (Suliqua) - for the treatment of adults with type2diabetes mellitus 1 Published 13 April 2020 1 SMC2235 insulin glargine plus lixisenatide (Suliqua®), 100 units/mL plus 50 microgram/mL and 100 units/mL plus 33 micrograms/mL solution for subcutaneous injection in pre-filled pens Aventis Pharma Limited, trading as Sanofi 06 March 2020 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug (...) and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission insulin glargine/lixisenatide (Suliqua ® ) is accepted for restricted use within NHSScotland. Indication under review: In combination with metformin for the treatment of adults with type2diabetes mellitus, to improve glycaemic control when this has not been provided by metformin alone or metformin combined with another oral glucose-lowering medicinal product or with basal
Association of magnesium intake with type2diabetes and total stroke: an updated systematic review and meta-analysis. The detailed associations between type2diabetes (T2D) and total stroke and magnesium intake as well as the dose-response trend should be updated in a timely manner.Systematic review and meta-analyses.PubMed, Embase, Cochrane Library, Web of Science and ClinicalTrials.gov were rigorously searched from inception to 15 March 2019.Prospective cohort studies investigating
Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Treatment in Type2Diabetes Mellitus: A Meta-Analysis. Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) have shown their beneficial effects on cardiovascular outcomes and multiple cardiovascular risk factors, including hypertension. However, the mechanism of blood (...) pressure (BP)-lowering effects of these agents has not been elucidated. This study aims to evaluate the effect of hemoglobin A1c reduction or body weight reduction with GLP-1RA treatment and SGLT2i treatment on BP changes in patients with type2diabetes mellitus. Methods and Results Studies were identified by a search of MEDLINE, EMBASE, and the Cochrane Central Register until June 2019. Meta-regression analysis was performed to evaluate the association between hemoglobin A1c reduction or body weight
Genetic variants in promoter regions associated with type2diabetes mellitus: A large-scale meta-analysis and subgroup analysis. Promoter plays important roles in regulating transcription of genes. Association studies of genetic variants in promoter region with type2diabetes (T2D) risk have been reported, but most were limited to small number of individual genetic variants and insufficient sample sizes. In addition, the effect of study populations and demographic characteristics were often
[Relative frequency of urinary tract infections in patients affected by diabetes mellitus type2 treated with metformin and SGLT2 inhibitor. Introduction and aim: The of this research was to conduct a network meta-analysis based on a systematic literature search to compare the relative frequency of urinary tract infections using sodium-glucose cotransporter-2 (SGLT2) inhibitors combined with metformin in the therapy of type2diabetes. Method: MEDLINE and EMBASE databases were searched (...) to identify publications of randomized, controlled trials investigating SGLT2 inhibitors combined with metformin in the therapy of type2diabetes and providing information on the frequency of urinary tract infections. Results: 10 165 unique citations were screened to identify 10 publications to be included in the network meta-analysis. The network meta-analysis showed reduced risk of urinary tract infections for low-dose ertugliflozin compared to other SGLT2 inhibitors (ertugliflozin 5 mg vs